Provided by Tiger Trade Technology Pte. Ltd.

Warrior Met Coal LLC

93.79
+3.994.44%
Volume:116.02K
Turnover:10.74M
Market Cap:4.93B
PE:22.55
High:93.96
Open:90.57
Low:89.86
Close:89.80
52wk High:111.42
52wk Low:61.87
Shares:52.57M
Float Shares:51.78M
Volume Ratio:0.76
T/O Rate:0.22%
Dividend:0.32
Dividend Rate:0.34%
EPS(TTM):4.16
EPS(LYR):1.08
ROE:10.04%
ROA:5.17%
PB:2.15
PE(LYR):86.84

Loading ...

RBC Capital Keeps Their Hold Rating on Warrior Met Coal (HCC)

TIPRANKS
·
13 hours ago

Warrior Met Coal is Maintained at Buy by UBS

Dow Jones
·
23 hours ago

UBS Adjusts Price Target on Warrior Met Coal to $102 From $98, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Warrior Met Coal price target raised to $102 from $98 at UBS

TIPRANKS
·
Yesterday

Madrigal Announces Publication in the Journal of Hepatology Demonstrating Consistent Rezdiffra Efficacy Across Common MASH Genetic Risk Variants

GlobeNewswire
·
Oct 06

Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Granted Orphan Drug Designation in Japan, Further Expanding Global Regulatory Recognition

GlobeNewswire
·
Sep 28

Warrior Met Coal (HCC) Tests Investor Patience As Blue Creek Fuels Undervalued View

Simply Wall St.
·
Sep 25

NYSE Order Imbalance 56938.0 Shares on Sell Side

THOMSON REUTERS
·
Sep 17

RBC Raises Price Target on Warrior Met Coal to $110 From $90, Keeps Sector Perform Rating

MT Newswires Live
·
Sep 16

WCLC 2026 | Leads Biolabs’ Opamtistomig (LBL-024) Oral Presentation Demonstrates Robust Response and PFS Benefits in First‑Line NSCLC

GlobeNewswire
·
Sep 14

Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation

GlobeNewswire
·
Sep 09

Press Release: Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Dow Jones
·
Sep 08

Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds

GlobeNewswire
·
Sep 02

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

GlobeNewswire
·
Sep 02

Parabilis Medicines to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Sep 01

Tokio Marine HCC International Acquires UK-Based Direct Commercial

MT Newswires Live
·
Aug 31

Press Release: Akeso 2026 Interim Results: Strong Commercialization Momentum; Io2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's

Dow Jones
·
Aug 28

IMMUNEONCO-B Advances Phase II Trial for First-Line Advanced Liver Cancer Therapy With Initial Patient Dosing Completed

Stock News
·
Aug 27

Warrior Met Coal CEO Walter J. Scheller Sells 50,000 Shares for $5.5 Million

Reuters
·
Aug 26

Warrior Met Coal Inc : Jefferies Raises Target Price to $125 from $110

THOMSON REUTERS
·
Aug 26